Alkannin Inhibits the Development of Ovarian Cancer by Affecting miR-4461 | Zendy

Yaowen Wang | Zendy; Jingfang Zhang | Zendy; Feipeng Wang | Zendy; Wenping Chen | Zendy; Jie Ma | Zendy; Honggang Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Alkannin Inhibits the Development of Ovarian Cancer by Affecting miR-4461

Author(s) -

Yaowen Wang,

Jingfang Zhang,

Feipeng Wang,

Wenping Chen,

Jie Ma,

Honggang Wang

Publication year - 2021

Publication title -

evidence-based complementary and alternative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.552

H-Index - 90

eISSN - 1741-4288

pISSN - 1741-427X

DOI - 10.1155/2021/5083302

Subject(s) - viability assay , flow cytometry , cell growth , western blot , cell migration , apoptosis , biology , cell , cancer research , microbiology and biotechnology , biochemistry , gene

Background Previous studies have shown that alkannin has anticancer, anti-inflammatory, and antibacterial effects. However, the effect of alkannin in the development of ovarian cancer (OC) remains unknown. Therefore, this study aims to elucidate the function of alkannin in OC progression.Methods RT-qPCR and western blot analysis were used to measure mRNA and protein expression. Cell viability and metastasis were detected by the CCK-8 assay, flow cytometry analysis, and transwell assay.Results Alkannin had no cytotoxicity toward normal ovarian cells, but alkannin can inhibit cell proliferation and induce apoptosis in OC cells. In addition, alkannin inhibited cell migration and invasion and blocked EMT in OC. Besides, upregulation of miR-4461 was found in OC tissues and cells, which was regulated by alkannin. More importantly, miR-4461 can inverse the effects of alkannin on cell viability and metastasis in OC cells.Conclusion Alkannin restrains cell viability, metastasis, and EMT in OC by downregulating miR-4461 expression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research